MSB 8.43% $1.35 mesoblast limited

Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-120

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 30,372 Posts.
    lightbulb Created with Sketch. 1858
    If you want an example of just a partner parking technology, look at how Teva behaved after acquiring Cephalon.

    Of course, they had no idea what they had, just a mentality of going for broke on DRUG clinical trials, equating stem cell technology with drugs, and then wondering why they messed up.

    Idiots!!!

    Or more accurately, bone headed number crunchers.

    (not the medical research staff who were from Cephalon originally and who steered the FDA through the developing of protocols process. They have been legends).

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.